Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry

Genetics in Medicine

Volumn 12, Issue 11, 2010, Pages 703-712

  Watt, Torquil ^a   Burlina, Alessandro P ^b   Cazzorla, Chiara ^c   Schönfeld, Dorothee ^d   Banikazemi, Maryam ^e   Hopkin, Robert J ^f   Martins, Ana Maria ^g   Sims, Katherine ^h   Beitner Johnson, Dana ⁱ   O'Brien, Fanny ⁱ   Feldt Rasmussen, Ulla ^a  

^a Rigshospitalet   (Denmark)

^b San Bassano Hospital   (Denmark)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Columbia University College of Physicians and Surgeons ^*  (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ GENZYME CORPORATION   (United States)

Author keywords

alpha galactosidase A deficiency; enzyme replacement therapy; health status indicator; lysosomal storage disease; SF 36 Health Survey

Indexed keywords

AGALSIDASE BETA;

ADULT; AGED; ARTICLE; FABRY DISEASE; FEMALE; GAUCHER DISEASE; HEALTH SURVEY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; QUALITY OF LIFE; RATING SCALE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; TREATMENT RESPONSE;

ADULT; AGED; ALPHA-GALACTOSIDASE; FABRY DISEASE; FEMALE; HEALTH SURVEYS; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; QUALITY OF LIFE; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649565697     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181f13a4a     Document Type: Article

References (35)

1. Desnick RJ, Ioannou YA, Eng CM. a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill, 2001:3733-3774.
2. Ries M, Ramaswami U, Parini R, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003;62:767-772.
3. Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Pediatrics 2005;115:e344-e355.
4. Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2008;64:550-555.
5. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002;81:122-138.
6. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242.
7. Ortiz A, Oliveira JP, Waldek S, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008;23:1600-1607.
8. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-128.
9. Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009;40:788-794.
10. Waldek S, Patel M, Banikazemi M, et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009;11:790-796.
11. Cole AL, Lee PJ, Hughes DA, et al. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 2007;30:943-951.
12. Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-327.
13. Miners AH, Holmes A, Sherr L, et al. Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res 2002;11:127-133.
14. Street NJ, Yi MS, Bailey LA, et al. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med 2006;8:346-353.
15. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
16. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75:65-74.
17. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-1557.
18. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease. Ann Intern Med 2007;146:77-86.
19. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-529.
20. Hoffmann B, Garcia de Lorenzo A, Mehta A, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005;42:247-252.
21. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374:1986-1996.
22. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-548.
23. Ware JE, Snow KK, Kosinski M, et al. SF-36® Health Survey manual and interpretation guide. Boston, MA: New England Medical Center, the Health Institute, 1993.
24. Ware JE. SF-36 health survey update. Spine 2000;25:3130-3139.
25. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001;45:384-391.
26. Bjorner JB, Wallenstein GV, Martin MC, et al. Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 2007;23: 731-739.
27. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology 2006;45:1238-1246.
28. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62:335-346. (Pubitemid 350105948)
29. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008;136:150-157.
30. Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007;71:576-588.
31. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43: 1478-1487.
32. Schwartz CE, Bode R, Repucci N, et al. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res 2006;15:1533-1550.
33. Beutler F, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill, 2001:3635-3668.
34. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760. (Pubitemid 33032930)
35. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609-1614.